Rhythm Biosciences (ASX:RHY) share price roars 8% on new cancer markets

The company is looking to launch into new markets.

| More on:
man jumping along increasing bar graph signifying jump in alumina share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Rhythm Biosciences Ltd (ASX: RHY) share price is on the move today. This comes after the company revealed its intentions to expand ColoSTAT into new cancer markets.

At the time of writing, the medical device company's shares are trading for $1.75 cents, up 4.79%.

What's driving the Rhythm share price higher?

Investors are fighting to get a hold of Rhythm shares after digesting the company's encouraging announcement.

According to the release, Rhythm advised that it has identified five new cancer detection markets to expand its platform technology.

As such, ColoSTAT is believed to hold multi-cancer detection properties, which could provide a foundation to expand the platform. Cancer markets include breast, cervical, lung, gastric, and pancreatic.

Rhythm's ColoSTAT is an experimental test kit that is being trialled as a low-cost, easy-to-use blood test to detect colorectal cancer.

It is estimated that around 850,000 people lose their life from colorectal cancer each year. In the United States, Europe, and Australia, over 130 million people aged between 50-74 years are unscreened for colorectal cancer. This represents an addressable market opportunity of more than $6.5 billion.

The strategic plan to expand the technological platform will form part of a research and development program. This is expected to follow a similar commercial pathway as to ColoSTAT.

The program will have access to $0.75 million worth of funds sourced from the company's last capital raising. In addition, the program could be eligible for the government R&D tax incentive rebate as well as other grants.

Rhythm CEO and managing director, Glenn Gilbert commented:

As we move closer to the launch of our initial cancer detection product ColoSTAT in 2022, the Company is making positive progress with respect to its broader strategy to leverage our cancer detection technology into other global cancer markets. Ultimately, Rhythm believes it can make a meaningful impact for improved health outcomes across millions of people around the world.

More on the Rhythm share price

The Rhythm share price has accelerated by 110% in the past 12 months, reflecting positive investor sentiment. Additionally, the company's shares reached an all-time high of $2.08 last month, before treading slightly lower.

At today's prices, Rhythm presides a market capitalisation of roughly $365.54 million, with approximately 208.88 million shares on issue.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Shot of a young scientist looking stressed out while working on a computer in a lab.
Healthcare Shares

Guess which ASX All Ords stock just crashed 23% on earnings miss

Investors are sending the ASX All Ords stock tumbling on Friday. But why?

Read more »

Lab worker puts hands in the air and dances around.
Healthcare Shares

Guess which ASX 300 stock just jumped 12% on FDA approval

Investors are piling into the ASX 300 stock following big US news.

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
Healthcare Shares

Broker says Telix shares could surge 80% higher after selloff

Let's see what Bell Potter has to say about this beaten down healthcare share.

Read more »

A doctor looks unsure.
Dividend Investing

Down 11% in a year, are CSL shares now a good income buy?

CSL shares have faced headwinds from potential US pharmaceutical tariffs.

Read more »

Five healthcare workers standing together and smiling.
Healthcare Shares

What does Macquarie think Resmed shares are worth after its result?

Resmed's share price is gaining momentum.

Read more »

A man with his back to the camera holds his hands to his head as he looks to a jagged red line trending sharply downward representing the ASX tech share sell-off today
Share Fallers

Why did the Telix share price just plunge 18%?

ASX investors are punishing Telix shares today. But why?

Read more »

A man pulls a shocked expression with mouth wide open as he holds up his laptop.
Healthcare Shares

ResMed share price is on watch for all-time highs

Powered by rising margins, global growth, and confidence from management, this sleep tech stock is turning heads again.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

Why this $7 billion ASX 200 healthcare share is now trading at a discount

With revenue surging, a leading expert believes the ASX 200 healthcare stock has been oversold.

Read more »